Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | WDR5 | P61964 | 2/20 | 0.57 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.57 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.57 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lansoprazole Sulfide SCHEMBL30053816 | 0.83 | RAB9A (1.00) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| Lansoprazole Sulfide SCHEMBL106519 | 0.83 | RAB9A (1.00) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| Lansoprazole Sulfide SCHEMBL1680900 | 0.82 | RAB9A (0.98) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| Lansoprazole Sulfide SCHEMBL6948284 | 0.82 | RAB9A (0.98) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| Lansoprazole Sulfide SCHEMBL1681186 | 0.82 | RAB9A (0.98) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| Lansoprazole Sulfide SCHEMBL1681462 | 0.79 | RAB9A (0.90) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| Lansoprazole Sulfide SCHEMBL8184520 | 0.78 | RAB9A (0.89) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| SCHEMBL29323856 | 0.75 | RAB9A (0.86) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| SCHEMBL6440543 | 0.74 | RAB9A (0.85) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 | |
| SCHEMBL9836498 | 0.74 | RAB9A (0.78) | CYP1A2CYP2D6CYP2C9CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683080-B2 | Stable iansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-23 | — | — | US | claimed |
| US-7622588-B2 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-24 | — | — | US | claimed |
| US-7683080-B2 | Stable iansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-23 | — | — | US | disclosed |
| US-7622588-B2 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-24 | — | — | US | disclosed |
| EP-1501824-B1 | A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE | TEVA PHARMA (IL) | 2007-10-10 | — | — | EP | disclosed |
| EP-1837335-A1 | A method for the purification of Lansoprazole | Teva Pharmaceutical Industries Ltd (IL) | 2007-09-26 | — | — | EP | disclosed |
| EP-1764364-A1 | A method for the purification of lansoprazole | Teva Pharmaceutical Industries Ltd (IL) | 2007-03-21 | — | — | EP | disclosed |
| EP-1743893-A1 | Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-01-17 | — | — | EP | disclosed |
| US-7060837-B2 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-13 | — | — | US | disclosed |
| US-7022859-B2 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-04 | — | — | US | disclosed |
| US-20050165059-A1 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2005-07-28 | — | — | US | disclosed |
| US-20050165060-A1 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2005-07-28 | — | — | US | disclosed |
| US-6909004-B2 | Method for the purification of lansoprazole | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-06-21 | — | — | US | disclosed |
| EP-1501824-A1 | A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE | Teva Pharmaceutical Industries Limited (IL) | 2005-02-02 | — | — | EP | disclosed |
| US-20040215021-A1 | Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-10-28 | — | — | US | disclosed |
| EP-1465890-A1 | STABLE LANSOPRAZOLE CONTAINING MORE THAN 500 PPM, UP TO ABOUT 3,000 PPM WATER AND MORE THAN 200 PPM, UP TO ABOUT 5,000 PPM ALCOHOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-13 | — | — | EP | disclosed |
| US-20040192923-A1 | Method for the purification of lansoprazole | TEVA PHARMACEUTICALS USA, INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040138466-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | TEVA PHARMACEUTICALS USA, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004046135-A1 | STABLE LANSOPRAZOLE CONTAINING MORE THAN 500 PPM, UP TO ABOUT 3,000 PPM WATER AND MORE THAN 200 PPM, UP TO ABOUT 5,000 PPM ALCOHOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004018454-A1 | A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138466-A1 | Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles | PDXK, PIR, STS | CYP1A2 80/4885CYP2D6 146/4885CYP2C9 105/4885 |
| US-20050165060-A1 | Method for the purification of lansoprazole | STS, SI, ATP6AP1 | CYP1A2 159/4885CYP2D6 15/4885CYP2C9 76/4885 |
| US-20040215021-A1 | Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol | ADH5, ADH1A, CYP2S1 | CYP1A2 25/4885CYP2D6 35/4885CYP2C9 27/4885 |
| US-20040192923-A1 | Method for the purification of lansoprazole | STS, SI, ATP6AP1 | CYP1A2 159/4885CYP2D6 15/4885CYP2C9 76/4885 |
| US-20050165059-A1 | Method for the purification of lansoprazole | STS, SI, ATP6AP1 | CYP1A2 159/4885CYP2D6 15/4885CYP2C9 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.